Millennium: Genes Are Not Enough
Executive SummaryTo push forward their gene-based discovery programs, drug firms need qualified targets, not simply genetic information. Millennium is trying to provide these targets—and its signing higher-value deals as a result.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.